Posted 11/2/2023, 5:38:07 PM
Eli Lilly Beats Earnings Forecasts as Diabetes and Cancer Drugs Drive Sales Growth
- Eli Lilly crushes forecasts as diabetes drug Mounjaro sales rocket 652% to $1.41 billion
- Mounjaro competing with Novo Nordisk's Ozempic; awaiting FDA approval for obesity
- Verzenio breast cancer drug sales up 68% to $1.04 billion, beating expectations
- Zyprexa antipsychotic sales $1.48 billion, topping estimates of $900 million
- Cut full-year earnings outlook, now sees $6.50-$6.70 per share vs prior $7.20-$7.40
